Building On Successes During Turbulent Times, SR One Closes $600m Fund II

$1.1bn Raised Since Spinning Out Of GSK

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.  

Wooden blocks with words 'Venture Capital'
SR One invests in new companies, early- and late-stage biotechs • Source: Shutterstock

The life science venture capital firm SR One has closed its second fund since it was spun out of GSK plc in 2020, bringing in $600m to back early- and later-stage biotechs in the US and Europe that are developing therapeutics across a range of diseases. CEO and managing partner Simeon George told Scrip that the VC firm offers start-ups both capital that can be difficult to find in the current financial environment and access to seasoned experts in the business of drug development.

SR One started its life as an independent venture capital firm in the midst of the COVID-19 pandemic, speaking with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.